Vale S.A. heads into the week after its Q2 print with a modest stock recovery, a sharply rising cost to borrow, and the freshly authorized buyback program still untested — a combination that makes the lending market the most interesting signal right now.
The standout this week is what has happened to borrowing costs. Cost to borrow has more than tripled over the past month, climbing from around 0.39% in mid-May to 1.62% now. The move accelerated in July: from 0.49% on July 10 to 0.86% by July 16, and then a further leg higher to 1.62% by August 4. That 234% weekly change is notable even if the absolute level remains modest by global standards. Availability, however, tells the opposite story — the borrow pool is vast. Availability runs at roughly 4,976% of short interest, meaning there are nearly fifty shares available to borrow for every one currently lent out. That is well above anything close to tight. Short interest itself is low, running under 2% of free float on ORTEX estimates, and the ORTEX short score of 26 ranks in the 91st percentile for low short pressure across the universe. The rising cost to borrow therefore reflects a pickup in demand for borrows rather than any structural squeeze — more a symptom of post-earnings repositioning than a sign of bears mounting a serious campaign.
The Q2 earnings reaction was muted. The stock fell roughly 1.9% the day after the July 31 release, a modest outcome given the wall of analyst caution that had built heading into the print. The prior week's Q2 preview noted Goldman Sachs cutting to Neutral at $16 and Morgan Stanley, Wells Fargo, and Scotiabank all trimming targets — the analyst data referenced in those previews was denominated in USD for Vale's ADR listing, and the current BRL-denominated VALE3 price of R$76.31 is not directly comparable to those USD targets. The Street's direction of travel is what matters: every major revision ahead of Q2 pointed lower, and the post-earnings reaction, while negative, did not accelerate the selling. The stock has recovered 2.2% in the session following the print and is up about 0.8% on the week, though still down 3.2% over the past month.
Valuation remains undemanding. The P/E runs at 8.8x, up about one turn over the past 30 days, while EV/EBITDA is close to 4.9x — both consistent with the deep-value framing Vale has carried for most of this cycle. The dividend score ranks in the 93rd percentile of the ORTEX universe, a reflection of Vale's history of substantial distributions even if the most recent dividend data in the snapshot is stale. The factor picture is mixed: the short score rank of 91 and days-to-cover rank of 85 confirm limited short-side pressure, but EPS momentum scores of 8 and 10 over 30 and 90 days respectively signal that earnings revisions have been running against the stock — consistent with the pre-Q2 target cuts.
Institutional ownership is stable at the top. Capital Research holds roughly 8.1% of shares, BlackRock 7.0%, and Mitsui 6.7%, with all three showing only marginal changes in their most recent reported positions. The freshly authorized buyback — up to 100 million shares, or 2.3% of issued capital — has not yet translated into disclosed repurchase activity. Whether Vale begins deploying that authorization into a still-soft stock will be the clearest near-term signal of management's conviction on valuation. The next scheduled earnings event falls on October 29, leaving the buyback execution pace, any update on Chinese iron ore demand, and the trajectory of that cost-to-borrow creep as the main threads to track between now and then.
See the live data behind this article on ORTEX.
Open VALE3 on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
